Welcome to the Quest Diagnostics Second Quarter 2019 Conference Call. At the request of the company, this call is being recorded. The entire contents of this call, including the presentation and the question and answer session that will follow, are the copyrighted property of Quest Diagnostics with all rights reserved. Any redistribution, retransmission or rebroadcast of the call in any form without written consent of Quest Diagnostics is strictly prohibited. Now I'd like to introduce Sean Bevec, Vice President of Investor Relations for Quest Diagnostics.
Please go ahead.
Thank you, and good morning. I'm here with Steve Ruskowske, our Chairman, Chief Executive Officer and President and Mark Guinan, our Chief Financial Officer. During this call, we may make forward looking statements and will discuss non GAAP measures. We provide a reconciliation of non GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected.
Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10 ks and subsequently filed quarterly reports on Form 10 Q and current reports on Form 8 ks. For this call, references to reported EPS refer to reported diluted EPS from continuing operations and references to adjusted EPS refer to adjusted diluted EPS from continuing operations excluding amortization expense. References to adjusted operating income for all periods excludes amortization expense. Finally, growth rates associated with our long term outlook projections, including total revenue growth, revenue growth from acquisitions, organic revenue growth and adjusted earnings growth are compound annual growth rates. Now, here is Steve Ruskowski.
Thanks, Sean,
and thanks, everyone, for joining us today. This morning, I'll discuss the 2nd quarter and review progress on our 2 point strategy, and then Mark will provide more detail on the results. Our volume growth accelerated in the second quarter, and we continue to build momentum through the first half of twenty nineteen. Our expanded network access continues to accelerate volume growth and our strategy to drive operational excellence improved efficiency. Both have helped offset the significant reimbursement pressures we are experiencing this year.
For the Q2, we grew revenues despite significant reimbursement pressure. Reported EPS was 1.51 dollars down about 4% from the same period of 2018. Adjusted EPS was 1.73 dollars down about 1%. Volume growth remained very strong at 4.4%, as the expected volume continued to accelerate in the 2nd quarter. Year to date, volume growth is now at 4%.
Now, let me briefly update you on 3 fundamental changes in the laboratory marketplace. They are PAMA, our expanded network access, increased consumerization of healthcare. First, PAMA driven reimbursement pressure remains a catalyst for a structural change in the marketplace. Our Medicare rates in the first half of twenty nineteen were down by 10% from the prior year, which is in line with our expectation. The next data reporting period remains scheduled for the Q1 of next year.
However, we are encouraged by the introduction of the Laboratory Access for Beneficiaries Act or LAB Act introduced in the house last month. The LAB Act would be a first step towards ensuring clinical laboratory service rates under PAMA are sustainable and Medicare beneficiaries have adequate access to crucial laboratory services. By delaying the next round of PAMA data reporting by 1 year, the Lab Act will provide all applicable laboratories with Lab Act would require a neutral third party to produce recommendations to Congress on how to improve the PAMA data collection and rate setting process. The second structural change affecting our industry is our expanded network access and payers becoming more focused than ever on driving better value in their lab spend. We are partnering with UnitedHealthcare to reduce excess costs created by out of network labs to further value to our customers and members.
On July 1, we became a UnitedHealthcare Preferred Lab Network provider and have begun an aggressive outreach campaign to physicians and UHC members. Beginning August 1st, providers referring members to out of network labs will need to complete an online approval process. In addition, Anthem has begun to implement its own strategy that lowers laboratory rates to hospital based providers, aligning them better with the rates currently paid to independent laboratories. Also, we continue to have conversations with other health plans on value based care initiatives and PLM like elements. Some of our recent contract extensions contain these features.
Finally, we continue to see increased attention on the variation in healthcare costs. Last month, the White House released a healthcare executive order designed to bring more transparency to the healthcare system. As consumers of healthcare get more information on the disparities in the cost of care, we believe this trend favors high value providers like Quest. Now turning to our recent progress and our strategy to accelerate growth, which has 5 elements: grow more than 2% per year through accretive, strategically aligned acquisitions expand relationships with health plans and hospital health systems, offer the broadest access to diagnostic innovation, be recognized as the consumer friendly provider of diagnostic information service, and then finally, support population health and data analytics in extended care services. So let me take you through a few highlights of our strategy to accelerate growth in the quarter.
As I said earlier, we continue to see revenue and volume growth as a result of our expanding network access. With the exception of Aetna, this growth is occurring across all of our major health plan customers. We recently signed a new professional lab services agreement with Catholic Health Services on Long Island, a large integrated healthcare delivery system in New York. Under the agreement, Quest will provide laboratory and supply chain expertise, as well as perform laboratory reference testing. We continue to believe hospitals will be increasingly more motivated to work with us on their lab strategy as they feel the impact of PAMA and lower commercial reimbursement.
In the era of advanced diagnostics, Quest is now participating as
a dense data laboratory in the
National Cancer Institute's MATCH Precision Medicine trial. This is the largest of its kind. The trial seeks to provide better outcomes for rare cancer types for which there is no standard treatment. T tests growth drivers in the quarter included tuberculosis testing with strength in both QuantiFERON and T SPOT, CAR U IQ and METAL testing. Each of these test categories drove strong revenue growth.
Our QuestDirect consumer testing business continues to gain popularity. Earlier this month, we launched a new consumer initiated Lyme disease test. We also drove sequential volume growth in consumer testing in each month in the second quarter. The second part of our 2 point strategy is to drive operational excellence. We remain on track to deliver 3% cost efficiencies for 2019 by continuing to drive increases in productivity.
Some examples are using digital technology to enhance the customer experience, drive growth, and reduce our carbon footprint. We have begun to eliminate paper documentation for Medicare beneficiaries who have financial responsibility for non covered services. This has reduced denials and contributed to our Invigorate savings. We're also working to help patients follow through when their physician orders a lab test. We started sending reminder emails to patients whose physicians have ordered tests for them electronically.
We're now sending text messages that remind them to nearly 1 third of our patients who schedule appointment online, which reduces the no show rate. Both of these the no show rate. Both of these initiatives are expected to help reduce the number of LIBOR orders that go unfulfilled. Now let me turn it over to Mark, who will take you through the financial performance. Mark?
Thanks, Steve. In the Q2, consolidated revenues were $1,950,000,000 up 1.8% versus the prior year. Revenues for Diagnostic Information Services grew 2% compared to the prior year, driven by strong volume growth and acquisitions, partially offset by higher reimbursement pressure and patient concessions. Volume, measured by the number of requisitions, increased 4.4 percent versus the prior year. Excluding acquisitions, volumes grew 2.9%.
As we've said before, not all volume is created equal, and we have regularly emphasized our strategy to be price disciplined. Recently, we had a few of our capitated contracts open for renewal. These contracts, while profitable in the past, represented large volumes at very low margins. In the competitive contract renewal process, apparently, one of our competitors was willing to offer lower rates that were prospectively very unprofitable for us. Therefore, rather than accept the rate cut, we walked away from the business.
Walking away had very little top and bottom line impact, but did create a 70 basis point headwind to organic volume growth and will do so throughout the balance of the year. We believe this is important for you to understand as you assess our relative volume performance. Despite that headwind, organic volume growth accelerated in the 2nd quarter, consistent with our expectations. Revenue per requisition declined by 2.3% versus the prior year, driven primarily by higher reimbursement pressure and patient concessions. Unit price headwinds were approximately 2.3% in the 2nd quarter.
This includes the impact of PAMA, which amounted to a headwind of approximately 120 basis points. As a reminder, the PAMA impact includes both direct cuts to the clinical lab fee schedule as well as modest indirect price changes for Medicaid and a small number of floating rate contracts. Reported operating income was $307,000,000 or 15.7 percent of revenues compared to $305,000,000 or 15.9 percent of revenues last year. On an adjusted basis, operating income was $352,000,000 or 18 percent of revenues compared to $362,000,000 or 18.9 percent of revenues last year. The year over year decline in operating margin was primarily attributable to higher reimbursement pressure and higher patient concessions, largely offset by strong volume growth and ongoing productivity improvements related to our Invigorate initiatives.
Reported EPS was $1.51 in the quarter compared to $1.57 a year ago. Adjusted EPS was $1.73 down approximately 1% from $1.75 last year. Cash provided by operations was $596,000,000 year to date versus $503,000,000 last year. And capital expenditures were $132,000,000 year to date compared to $151,000,000 a year ago. Now turning to guidance.
Our outlook for 2019 is as follows: revenues expected to be between $7,600,000,000 $7,750,000,000 an increase of approximately 1% to 3% versus the prior year. Reported EPS expected to be greater than $5.29 and adjusted EPS to be greater than $6.40 Cash provided by operations is expected to be approximately $1,300,000,000 and capital expenditures are expected to be between $350,000,000 $400,000,000 Before closing, I'd like to review a few reminders as you think about the remainder of 2019. First, we continue to expect more than $200,000,000 of reimbursement pressure this year due to PAMA, our new in network health plan contracts in 2019 and the modest reimbursement pressure we typically experience each year from other sources. 2nd, we continue to expect that volumes will gradually increase as we progress through 2019 just as they have in the first half of the year. 3rd, we have approximately one extra revenue day in the 3rd quarter.
Finally, we expect the strongest revenue and earnings growth in the Q4 of 2019 due to an easier comparison. I'll now turn it back to Steve.
Thanks, Mark. Well, to summarize, our volume growth accelerated in the Q2 due to our expanded network access, and we continue to build momentum through the first half of twenty nineteen. Our strong volume growth combined with our strategy to drive operational excellence enabled us to help offset the significant reimbursement pressures we're experiencing this year. We're excited to be back or be a new 3rd lab network status with UnitedHealthcare and the opportunities to extend this approach to other players in the marketplace are with us. And then finally, we believe we are well positioned to meet our commitments in 2019.
Now we'd be happy to take any of your questions.
Thank you. We will now open it up to questions. Our first question comes from Ralph Giacobbe with Citi. Your line is open.
Thanks. Good morning. Ralph, if you can hey, good morning. Can you maybe help on how volume progressed through the quarter, if you're still seeing a build sort of month to month or if it has stabilized? And then I just wanted to kind of clarify what you said around sort of the capitated contract that you lost.
Is that a regional or a national contract? And then just help us on kind of the timing on when it happened and just broader thoughts. Obviously, there's a lot of discussion around the open network approach and sort of structural changes there. So this goes sort of against that tide. So maybe flush that out a bit for us.
Thanks.
Sure, Ralph. So because we have these artificial conventions called fiscal years, months, quarters, etcetera, there can be some noise. So if you look at our volumes throughout the quarter, they didn't accelerate each month because of the calendar. However, when you look at there's something else we look at, which is requisitions per day on an apples to apples basis, they did absolutely continue to grow throughout the quarter. And as I noted in my closing comments, that is our expectation for the balance of the year.
So we know throughout each month, the beginning of the year in Q1, we saw accelerated volume growth and then throughout the Q2 when you look at an apples and apples comparison, absolutely we continue to strengthen despite that 70 basis point headwind. The headwind itself was actually a handful of regional capitated contracts. They were exclusively capitated. There was no paper service element in those contracts.
And as I
said, they were very large volumes and low margins. And they started feathering in the beginning of the year, but really fully hit us largely in the Q2.
Our next question comes from Kevin Caliendo with UBS. Your line is open.
Hey, great. Thanks for the question. This is Adam Noble in for Kevin. Hey, Adam. Hey, just wanted to see if you could size in the second quarter what the benefit to the organic volumes was from Managed Care Access versus just general market growth.
And do you expect to have further penetration of those contracts in the back half?
Yes. Let me start and I'll pass it to Mark. First of all, we continue to talk about that. We're always looking at the marketplace and trying to understand what's going on in the marketplace. And with all our measurements and metrics that we have and we've talked about for many years now the same store analysis, we still believe the market is stable.
We see stable volumes in our physician accounts. And also our hospital business seems to be stable versus the prior year. So Mark, could you like to add some color beyond that?
Yes. So it's hard tease out specifically, I think to Steve's point, we don't think the market has been accelerating in terms of its growth. So we say market access, if you're asking specifically around United versus more prepared remarks, other than Aetna, we're obviously, we had a major competitor who entered that contract. We were the sole national. We're growing in every single major health plan.
So in terms of market access, it's not just United. Obviously, it just makes us more competitive. It enables us to win the office. And so therefore, we're seeing growth across the board, not just limited to United or Horizon.
Got you. And if I could just sneak in one more. Just any update around the M and A pipeline? Neither you or your main competitor announced any acquisitions year to date. Is that a more function of an elongated conversion timeline or are you seeing any change to the size or nature of the pipeline?
Yes. So you saw in our results that we inched up a little bit in Q2 versus Q1 in terms of the amount of our revenue from acquisitions. So we're feathering in some of the acquisitions and they're delivering well. 2nd is, as we said before, we'll continue to say it. Our funnel remains strong.
We have a number that support our ambition to be close to 2% this year and into the future. So we keep on working on that. And just close with what I said in my remarks, the pressures that we see are now becoming real and becoming more visible. And those pressures are with PAMA cuts. Some of that does extend itself, particularly for hospital outreach outreach businesses into Medicare rates.
And then the commercial changes that I talked about in my prepared remarks are clearly going to impact the hospital marketplace and the independent lab marketplace. And so because of that, we continue to have a lot of conversations around integrated delivery system lab strategies. And you again saw that we announced this new deal with Catholic Health Systems out of Long Island, which is another supporting proof point that we continue to advance our strategy on that front. And the pipeline will be there to support our strategy, as we indicated.
Yes. Steve commented, as you noted, we didn't do any transactions in the 2nd quarter. But Steve commented, we did get more growth from M and A. We closed a deal regional acquisition voice and volume in the Q1. So obviously, we've got the 1st full quarter of growth from that in Q2.
And I would say there's no attitudinal change in terms of people's view around potentially getting out of outreach our hospital customers and certainly some of the regional labs are feeling the PAMA pain. I think the interesting dynamic we've seen is that actually more of the conversations with hospital systems are getting broader. So it's not just about outreach, but actually about doing a PLS deal, doing a reference deal and potentially selling the outreach like we did with PeaceHealth last year. And that's a positive. But on the other side, those take longer.
So an outreach deal can be done much more quickly. So that dynamic has emerged a little bit over the last year or so, which is does add a little bit to the time frame to get these transactions completed.
Our next question comes from Ross Muken with Evercore. Your line is open.
Good morning, guys.
How are you doing, Ross?
A bit on the cost side. I mean, it seemed like some pretty strong sequential OpEx management. I know you had called out in Q1 some pull forwards, but give us a little color. It looks like restructuring ticked up a bit and your depreciation came down. So just sort of how you're tracking on your cost plan and sort of some of the realization of the main program versus some of the other timing elements that played out?
Yes. So sorry again, Mark will follow. It's just we continue to execute our plan for 2019. We indicated in our Q1 that we have planned for a number of restructuring efforts to start to kick in, start to kick in, in the second quarter. That will continue in the back half of the year.
So we feel good about that. So we think we have our handles on the levers of cost in the right way. And then second, Ross, is we continue to drive our operational excellence program. I did say in my remarks, it's 3% of our cost base. Remind everyone that's about $200,000,000 And we continue to yield good results from that.
We continue to see good productivity across the board. And yes, that's an expense areas, but also in the cost of sales. And we will continue that into 2020 2021.
So Mark? Ross, thank you for reminding everyone. But really, the 2 drivers, if you look at Q2 versus Q1, One was the investments that we did at the beginning of our new access in terms of some marketing, adding some commercial resources, etcetera. Certainly, we haven't stepped back on the commercial resource. We have stepped back on some of the marketing campaign information.
There were also some things that were expensive because we were betting on commenting, patient service centers adding some logistics, assuming the volume would come, making sure we were in position. Now that volume is coming, it just became the classic typical cost of sales. So it's not incremental expense. And then the other key driver was the restructuring that we completed at the end of the first quarter, which has taken out on a run rate basis a substantial amount of expense that will continue throughout the balance of the year and going forward.
Our next question comes from Stephen Baxter with Wolfe Research. Your line is open.
I wanted to try to understand the sequential improvement in the decline of revenue per acquisition. So obviously PAMA is a known quantity at this point. So I was wondering if you could update us on some of the other moving pieces there, whether it's commercial pricing or bad debt. I guess the other potential is that maybe this capitated contract you discussed had some kind of impact. Any color you can give there is very helpful.
Bart, do you want to take
me through the math?
Yes. So typically, in terms of commercial pricing, typically those contracts run-in the calendar year. There's been a couple of exceptions where we've done things in the mid year. So there really wasn't anything in terms of commercial price changes between Q1 and Q2 nor as you noted, is there anything different than PAMA. So this was really driven by mix.
Some of it was some test mix. You do have some seasonality that can drive things up or down in the rev per rec. But as we've noted, that doesn't always necessarily directionally aligned with profitability, even though it does drive changes in the rev per rec. And then, of course, the losing some of the capitated revenue certainly is a lift from a mix perspective. And then finally, a PLS is a driver as well, because as we've shared in the past, those tend to be more basic requisitions on a lot of complex testing.
And certainly as the POS growth business grows disproportionately to the rest of the business, it can add or put a drag on our revenue per rack. And then finally, patient concessions. When you look at the patient concession rate in the Q2 versus the Q1, it was improved. And a lot of that is really the result of the efforts that we've had to really improve the collectability of a lot of the tools that we put in place at our patient service centers with our real time adjudication to give people that cost upfront, ability to collect the credit card, as well as really working hard with our partner Optum to get better information on patients, do a better job of presenting the bill and overall collecting at a higher rate.
Our next question comes from Ann Hynes with Mizuho Securities. Your line is open.
Hi. Good morning, Ann.
So in your prepared remarks, you did talk about all the payers initiatives, what they're doing on the PLL side. You specifically mentioned Anthem and some recent contracts include some PLN aspects. Can you just go into more detail on what you're talking about? Thanks.
Yes, sure. Well, first of all, go back to the opportunity this year. The biggest opportunity is it's best to access of insurance access we have for over a decade. And the PLN is going to be nice to have and it will provide some more momentum and we believe it's a nice lever for us. And yes, we talk a lot about the effect that will have with United, but as we talked about, we're having a number of conversations with other payers.
And then finally is some of the contract extensions that we already have signed include some of the elements that we will talk about. United will be releasing more and more as we go and they will provide more details. As I did mention in my remarks, if you're out of network, it's going to require more authorization to allow that to happen. So that's one point. 2nd is what we've said in the past is there clearly will be a benefit design change, so less out of pocket costs for consumers.
And then 3rd, there will be physician incentives. So when you think about what's going to be the big elements, it's all around benefit design, less out of pocket cost for consumers, physicians being managed to drive towards that preferred lab network. And then finally is really making sure there's no leakage to out of network. And it will be stronger than ever with United and we see a lot of momentum with other payers as well. So more to come on that end, but we're off and running and working this hard and we do believe it's going to be an additional lever.
But don't let it overshadow that the biggest opportunities with best in network. And what I also said in my remarks, yes, we got good growth, obviously, from the United, but all our major health plans grew with the exception of Aetna, where we actually did expect a modest decline, which we saw. So just
to add in, I think Steve's point that a lot of the benefits of the PLN type elements is still in front of us. So it hasn't driven the volume growth at this point. It's an enabler to continue to drive. So what are some of those things? And it's going to be different by payer type, but these are the concepts that we've talked about and various payers have embraced.
Some of these or all of these to a certain extent. A lot of them are rooted in us getting additional payment or bonus payment, what have you, as we've shown the ability to steer work to better value away from higher cost providers. So we've gotten that in a couple of contracts recently where we have a metric and a way of showing that as they save money, as their members save money, that we get a piece of that. And so we're aligning those incentives. Another one is around treatment of pre authorization, which is a huge driver for denial.
So in a couple of payers, we've gotten as have our chief competitors, some others, But the labs that have shown themselves to be high quality, actually differentiate themselves positively from a service perspective and other things around their panels and how they conduct themselves. We've actually gotten a status where they waived the pre authorization. So it's an advantage for us from a physician's ordering perspective that the payer says, we know if you send the work to these following labs that we're going to be okay with it. So therefore, you don't require a pre auth. So that's another element that we've gotten in some of our contracts.
Steve mentioned some of the 0 out of pocket and some of the payers are coming up with products that they are offering that obviously we're going to market. We'll see the adoption rate and then some other payers have voiced an interest in going heavily in that kind of plan benefit design. So again, it's not as if there's a one size fits all. That's why we talk about these being in elements in some of the other payers. And then finally, there's a lot of interest in kind of sharing the, we'll call it, the win fell game from our Outreach acquisition.
So when we buy a hospital outreach business, obviously, those commercial rates immediately go to our negotiated rates, which is a huge savings for patients, huge savings for the payer and the notion that, hey, this is good for all stakeholders and we should share in some of that value. So those are a couple of details that certainly have gotten a lot of traction with the payers. And as Steve pointed out, that is in front of us. So when I say in front of us, we've gotten those in some of the contracts, but obviously we have to perform and we have to earn those and then those are off-site going ahead.
Operator, next question.
Our next question comes from Lisa Gill with JPMorgan. Your line is open.
Good morning, Lisa.
Good morning. I'm just wondering if you can maybe just give us an update on your consumer retail strategy. I didn't hear anything in the prepared comments this
morning. Yes. It's one of our 5 strategies for growth. And several parts of being the most consumer diagnostic integration service provider. We have talked about in the past, just to remind everyone, we have really digitized and brought our patient experience into today's world.
And so when you walk into a Quest patient service center, it will remind everyone of the other experiences they have in their other experiences as a consumer, not as a health care experience. So a lot of progress there. The second is we continue to make progress on the tools and the access to the information. So the MyQuest app, which is our smart phone app, has continued to expand its registration and will continue to expand the capabilities so you can schedule appointment online. You can see wait times at patient service centers, you obviously get your results.
And we now have over 7,000,000 registered users, which is remarkable. And then the last piece of this, which is your specific question, is the physical presence we think is quite important. So we have continued to manage our retail strategy and move our patient service centers to a more retail setting over time. Right now, we have roughly 200 ish patient service centers between our Safeway relationship and Walmart. Walmart is about 70 of that.
And we continue to evaluate the best path forward to eventually have about 50% of our 2,200 patient service centers in more retail like settings. Now what I'll also share is we have said that roughly 25%, let's call it 500 of our current patient service centers are more retail like, not all with retailers. But as we evolve over time with our current retail relationships and with possible others, that number will grow to be about half of our fleet of patient service centers. And our experience in those is quite good. We believe that the patient likes the experience better, it's much more consumer experience.
Our employees are providing us slightly better, we can consolidate our operations into fewer sites. And the patient it. They walk in, they can walk around with a pager, they can do some shopping, they can eat after they've been fasting. So overall, that from our perspective is quite good. And then our relationship with the retailers is good as well because they benefit from that short store traffic.
So we feel positive about the response and our results so far and we're continuing to drive it.
The only thing I would add, Lisa, is that there's always some outliers. But if you look at on average, our retail draw sites continue to increase the amount of activity. We had the highest average amount of draws in our Walmart sites in June that we've had since we started this. So we're very happy with the amount of traffic we're in and we're feeling really good about the presence. And of course, our volume is growing, so there's things that are probably driving it.
But part of it is awareness. People are starting to figure out we've got these draw sites in Walmart and getting comfortable going there, and we would expect that to continue over time. Next question, operator?
Our next question comes from Kevin Ellich with Craig Hallum. Your line is open.
Thanks for taking the question. Steve, in your prepared remarks, you commented about Anthem shifting hospital based rates to independent lab rates. We saw something, I think, at lab economics about that was shifted for pathology. Can you give a little bit more color? Is this for all of the tests that are being done in hospitals or just pathology?
And then are you seeing other commercial payers follow this doing something similar? And then what will that do for your hospital outreach and PLS deals?
Yes. So I would just say as an overarching comment and it's embedded in our introductory remarks that we have PAMA. And PAMA to some extent is independent of what's happening on the commercial side. But we now continue to see pressure from commercial payers on hospital outreach. So, yes, we mentioned Anthem, but I'll also share that there's pressure from other payers, particularly with those that we work with to push down the rates for all the ancillary services.
And I would obviously, that includes lab, it includes radiology, it includes other ancillary services that are provided by the hospital. And Kevin, two parts of this. One is just in general to move more of the volume to most the highest value based provider like ourselves in the lab. But second is because the added cost to consumers And the consumers, given the high percentage of employer sponsored health plans that have high deductibles and the high out of pocket costs for these expensive hospital based services, the payers are looking at more aggressive strategies to normalize the rates more. So yes, we call that Anthem is proactively having a strategy, but we see this in many other places with many other commercial payers that are pushing back on what they've done in the past with ancillary services in general, but specific to lab.
So Kevin, I would encourage you to ask Anthem directly. There is a I know they've led
a couple of places with pathology. There's a publicly available document, which we are referencing. And as you might imagine, before we said anything, we checked with them to make sure they were comfortable with the statement that we were attributing to them. But I would for more detail, I would encourage you to ask Anthem about the schedule and how broadly they're doing it and so on. But there is something they've published and put out in the public domain.
Yes. And in Part B of this, Kevin, I mentioned in my remarks, the movement across the country towards more price transparency. As you know, there's wide variation in our marketplace with ourselves having what we believe the best value proposition on the planet, great quality, great service at some
of the lowest
prices. And in that regard, actually there a story today in the journal, which speaks to a number of the payers providing apps services, if you will, to provide visibility to consumers to do a better job of shopping. And they call out Anthem, as we did, but others, including Humana and UnitedHealthcare, that are working proactively as by way of another example to help consumers manage their cost.
Operator, next question?
Our next question comes from Jack Meehan with Barclays. Your line is open.
Hey, Jack. Good morning.
Hey, Jack. Good morning. Just given some of the recent progress in terms of the commercial contracting that you talked about, I was wondering if you could give us some line of sight into how you think commercial unit pricing is shaking out for 2020 and just how that compares to the long term guidance that you laid out at
the Investor Day last year?
Mark? So I'm sure you appreciate, Jack, I'm not going to speak to 2020. We're in very good shape in terms of where we stand with the commercial payers and the need to extend contracts. So there's no surprises that anyone should expect. We're in great shape.
And around the pricing, I mean, obviously, those prices are already set in So those could be some upside. However, if you recall, I gave you a pretty broad range on the revenue CAGR. So what I would tell you is that within those scenarios between the low end and the high end, we've contemplated all the different kind of outcomes that might happen, including obviously how quickly we gain our fair share in some of the new network access contracts and then how quickly and to what extent we earn some of those potential incentive payments. So I would say everything within the multiyear outlook that I provided has been reasonably contemplated, and that's why we give a broad range.
Our next question comes from Dan Leonard with Deutsche Bank. Your line is open.
Thank you. Question for Mark. Just wanted to clarify your organic volume growth expectations in the second half of the year. So you said that volume should gradually increase as you progress through the year. The comps do get tougher.
So are you expecting organic volume growth in the back half of the year to be higher than this kind of rounding to 3 ish percent you've delivered in the first half of the year?
Yes. So we absolutely expect the revenue, despite any sort of comps I'm sorry, the volume to increase on an organic basis. So it may not happen every week, it may not happen every day, every month. But when we look at Q3 and Q4, we expect to continue to see improvements versus the Q2 in our year over year organic volume.
Our next question comes from Donald Hooker with KeyBanc. Your line is open.
Great. Good morning. So I
just wanted to ask maybe a question on the PLS business. I think in the past you guys have targeted some good some optimistic outlook. An optimistic outlook for this is I think you've talked about 50 basis points of revenue growth in going forward or something a revenue growth tailwind going forward from just PLS deals. Are you on track with that with these deals? Like there's been a couple.
I'm not sure if there have been others that you haven't announced. But in terms of trying to sort of size these deals and sort of put you on a trajectory with PLS? Can you kind of reiterate that or discuss
that there? Yes. So as we shared with you, our last practice is one of which is to proactively have conversations with integrated delivery systems on their lab strategy. And also the access is helpful there as well, because the within geographies where we had issues with not having good access with some of their patients. So this continues to be a nice growth driver for us.
We announced the Catholic Health Systems deal in Long Island. We did announce some other relationships last year and they extended it and built throughout 2019. And I'll just close with Sam, the funnel continues to build. In the past, we've shared when we go in and we have conversation with the last strategy, it starts with how we can make them more efficient. And this is what we call professional lab services or PLFs.
And this is their inpatient hospital lab and it's a cost center. So we could save them anywhere from 10% to 20% of their cost. So that's an opportunity. 2nd, as we get into that, then we work with them to rationalize and to become more efficient in their sophisticated reference testing that they send out. That's another opportunity.
And then the 3rd piece, it's very new to not to have this conversation. We then have a conversation about their outreach where they're in the commercial marketplace with us. It doesn't make sense for us to them to continue to be in it or should we buy their business. So that those discussions continue to progress. We have a bigger funnel than ever.
We backed out the United States. We know all the integrated delivery systems with the outreach businesses. We know those that have substantial number of beds in their cost centers, and that continues to be a nice growth driver for us.
Our next question comes from Patrick Donnelly with Goldman Sachs.
Good morning.
How
are you? Steve, maybe just on the contracts you walked away from, can you just provide some more color there? It's a bit surprising to hear are once again being aggressive on price. It felt like there had been a bit of a lull there. Given the PAMA backdrop, the industry seemed to realize price discipline was the best way to fend that off.
So maybe just some more context around what you're seeing. What would lead these other labs to be price competitive given this backdrop?
Want to take just one more?
Great question for you to ask our competitors. So that's not something we can speak to. Obviously, we control our own view towards pricing. We've been pretty vocal and consistent that we feel our price is already really good. There's an awful lot of competitors in this marketplace that have prices that are multiple of our price and we are an excellent value.
There was no need for Quest to offer a lower price. So in terms of other people's motivation, to drop price further in some instances, that's a question you would need to put to them.
Our next question comes from Ricky Goldwasser with Morgan Stanley. Your line is open.
Hey, Ricky.
Good morning.
Ricky, we can't hear you.
Hi. Sorry, this is Alexa on for Ricky. Can you hear me?
Yes, we can.
Great. Thanks. I had a little line trouble there. I wanted to come back to your expectations for the second half of the year. You beat the quarter, but maintained guidance, which sort of implies a lower second half earnings growth than what the Street is currently modeling.
Are there any headwinds you feel the Street isn't factoring in for the back half of the year? I guess, can you just give us a sense of the puts and takes here and what the sources of upside to the guide could
Let me just start and then Mark will get into the details. What we showed in the first half is we've delivered on what we set for expectations that we wanted to show momentum build throughout the first half of twenty nineteen, and we did. So we're pleased with the results in the first half. 2nd is we're midway through the year, and we thought it was prudent at this point to maintain our outlook, not get ahead of ourselves. But what Mark said earlier is and what we've said about this year, but also in general about the growth opportunities in front of us, it will continue to build throughout 2019.
But this is not just a build for 20 19. It will include the build in 2020 2021. So Mark, a little more color around the rest of the year. Yes.
So we are not in any way influenced by what the Street's view is in the back half. What we're when we do when we give guidance is really what we think our shareholders and stakeholders should understand from our perspective. So when you look at the first half, we're very pleased with our results. We feel like we're on track. It's still halfway through the year.
Of course, in the back half, we have things that sometimes happen that are beyond our control, like hurricanes and snow in December and so on. So at this point, we just felt that there wasn't any need since we've given a floor and not given any sort of a range. So there's nothing negative in terms of our signaling for the back half. We are on track to do what we expected, which is to do at least $6.40 We're obviously feeling good, I think, as many others with what we've done in the first half, but we'd rather just continue to perform and then obviously cross our fingers around any sort of weather events and other things that might impact the back half. But certainly nothing operational that we're signaling or that anyone should be concerned.
Operator, next question.
Our next question comes from Bill Quirk with Piper Jaffray. Your line is open.
Hey, Bill. Hey, good morning, everyone. So kind of a multi part question here guys. First, I think the answer is no. But is there any negative effect from Anthem?
2nd piece is with respect to the capitated contract loss. Was that contemplated in the original guidance? And then lastly, just any comment with respect to your genomics business, given that the principal supplier into that industry had obviously cited some challenges in that space a couple of weeks ago? Thank you.
So I'm sorry, I didn't catch your question, Will, on Anthem. Yes, the first part.
Yes, the first part of the Anthem question was just, I think the impact here is predominantly for hospitals. I just want to confirm, guys, that you're not seeing any negative effect from some of the Anthem reimbursement changes that they're implementing?
Yes. No, we have a contract, multiple contracts with Anthem actually. We contract with them regionally that we have a negotiated price and so on. And certainly, we are not in the zip code of the hospitals that they are now starting to say need to be rationalized. So this is really a movement to get everyone, it's not targeting anyone specifically except for the outliers to be more at a more consistent rate.
So we feel we're already in that zip code. And certainly, there's going to be no changes in the current timeframe because we have contracts with Anthem. On the capitated, we really don't give guidance on volume. So was this a possibility that we contemplated? Yes, certainly.
But as I pointed out in my prepared remarks, this has minimal impact to our revenue and certainly no impact to our bottom line. So really, it's more of a volume effect. And we've tried to encourage our stakeholders to not to pay quite as much attention volume
for this very reason.
So we thought given the magnitude of this change, we want to make sure that you understood there was a big volume shift from us to others or to another direct headwind, but really no financial or economic negativity to us, just volume. And the last part, Bill, I had
a hard time hearing that as well.
Just a comment, Steve, on your outlook for the consumer genomics business, given what one of the principal suppliers had a couple of weeks ago?
Yes, got you. Yes, thank you. As we have the relationship with Ancestry. That's a good relationship that continues to build. And there's no material effect on our growth, plus or minus.
So I would just say, in general, fairly stable. 2nd is, I did remark about our consumer testing business, which affords us a nice platform that is growing nicely and we're very pleased with this pickup around our general diagnostic testing. And I mentioned that we just introduced a new line to these tests. But we're going to use that as well as a platform for consumer genetics in the future. So more to come.
But overall, stable environment as we see it. As you know, we're not the only provider to Ancestry at this time. And it's not a big piece of our revenue. So stable business for us at this point and still good opportunity in front of us.
Operator, next question?
Our next question comes from Derik De Bruin with Bank of America Merrill Lynch. Your line is open.
Hi, Derek.
Hi, Derek. Good morning. Hi. Hi. Could you talk a little bit about
the esoteric testing business and just sort of volume and mix trends within that and sort of how is that impacting the overall revenue per acquisition? Just is pricing getting better, reimbursement stable, Matt? Just any additional color would be great.
Yes. Well, so first of all, the term esoteric is an industry term. We have defined our And we don't break out specifically that business and provide color. But and we don't break out specifically that business and provide color. But in general what we've said in the past, it's a business and within the quarter, we felt good about the progress we've made in that within the quarter, we felt good about the progress we've made in that business on a number of fronts.
We have some good growth in some portions of women's health. And then in addition to that, we define esoteric. It typically includes a toxicology presence. Prescription drug monitoring continues to be a nice big growing business for us. We're pleased with the progress in the quarter as well.
And just in general, I think our esoteric or more sophisticated testing, we had good year on year comparisons better than last year in our hospital presence. That's not all esoteric, but in general, a lot of it is. And then as we pull more growth in our general diagnostics business that typically will also pull some advanced diagnostics or esoteric business as well. So overall, as we raise the tide, it's going to help all the boats in the harbor, including advanced or esoteric as well as general diagnostics.
Operator, next question?
Our next question comes from Matt Larew with William Blair. Your line is open.
Hi, good morning. Thanks for taking
my questions.
Obviously, PAMA was an initial catalyst for hospitals and health systems thinking about the future of their lab business. But it sounds like the preferred lab network, both specifically with United and then more broadly as payers are being more aggressive with the way they think about laboratory testing may actually be perhaps a more dramatic catalyst. I wonder if you could just discuss the conversations you're having with hospitals and health systems, be it for outright M and A or PLS arrangements and how payer behavior has started to change those conversations?
Yes. Sure. First of all, if you recall, we've been talking about 3 changes in the marketplace, the panel of that. And one could argue, it really just got started in 2018. And because of some of the nuances of how the payment works, it was somewhat muted related to some of the offsets, the fee reductions, which grew about 10%.
So the 1st year, 'nineteen is the 2nd year. It's a full year, no muting of any of the effects. And then we're going to have another effect in 2020. So that is starting to become more visible and hospital outreach businesses and administration of hospitals are becoming more aware of that. And then the second part of that is it will spill over even has already spilled over to Medicaid.
Typically Medicaid in all states is lower than Medicare. And then finally, as I talked earlier, lot of the commercial payers are pushing back on the wide discrepancy of healthcare costs, particularly in our space, in laboratory wide variations where hospital rates could be 2 to 10 times higher than our rates. And then the last piece is the reason why they're pushing on this is because consumers are paying for more and more health care every day. Employers are asking questions about it and it's getting visibility in Washington. So those three changes in the marketplace are getting a lot of visibility for from administration of any integrated delivery system.
And then second is small regional operators clearly see a different environment going forward. But sometimes we're asked the question about any we're in. Okay. And anything we do. I would say in this front with those three structural changes, we're still in early innings, but it's building momentum as we get into the middle of the game.
So I think we're now beyond the start and we're starting to get a lot more visibility to it and there's going to be a lot more change in 2020 and that's going to be affecting decisions of whether hospitals stay in the business or whether the regionals continue to operate as the operator considers their options and considering selling the business. And it's part of our strategy to be a consolidator in this marketplace since we are the leader.
Next question, operator?
Our next question comes from Eric Caudwell with Baird. Your line is open.
Hey, thanks very much. Most of my topics were covered. But on these capitated contracts, we know from past filings that they were in total representing about 11 percent of volume and 3% of your revenue. Were the contracts that you specifically walked away from the low end of a capitated contract because you're seeing absolutely no impact on revenue. So I'm just trying to understand typically capitated contract is a quarter of your average profitability.
So were these the low end of that range? Or is there perhaps some slight impact from this change? Thanks very much.
Yes. So they were definitely low margin as I referenced. We've actually maintained some of the work at a higher rate. So there's an offset to the lost OM because in the particular state that this took place, they're obligated to pay us for a subset of tests even if we're not in contract and they're obligated to pay us at a rate that's much higher. So therefore, I didn't get that detail in the prepared remarks, but that's why there's really very little, if any, OM impact.
That's a partial offset to the revenue, not 100%, because it's lower volume, less revenue even though at a higher rep much higher rep per rep, but not enough to compensate in total. So it's within the certainly rounding in our overall annual revenue. It's not a huge number with that offset. And on an O and M basis, it's really had no impact because we continue to get paid for some of the work that we've maintained.
Last question, operator?
Our last question comes from Mark Massaro with Canaccord Genuity. Your line is open.
Hey, Mark. Hey, guys. Thanks for the questions. I wanted to ask about in regards to your consumer initiatives, QuestDirect is certainly one of the initiatives. I know it seems fairly early and other lab providers are doing similar pilots, But can you just speak to any traction you're getting there?
Maybe can you help us think about whether or not that has moved the needle in terms of actual orders coming from new types of individuals? And then my second question is on the Clinical Trials Connect program. Also seems like it's early days, but can you speak to any wins there that gives you confidence that this can grow in the future?
Okay. So first of all, on direct to consumer, we've been at this for a while. We've actually started to test the water. We built a business with a relationship with the New York Football Giants and called Sports Diagnostics and really put our toe in the water of understanding very specific segment, how we can market our product directly to consumers, how we can fulfill that order because it's a different order fulfillment chain resulted. So we had to build some capability years ago to do that.
And then second is we actually tested the waters on our general diagnostics business in the state of Arizona several years ago. We have a joint venture partner with Banner Health. And as you recall, one of our competitors given that in that state, they passed legislation where consumers no longer needed a physician order to order laboratory tests. And so we actually priced out about 100 tests and found out in fact in Arizona there was a market. And so we took that success and we moved it to Missouri and to Colorado.
And then this past fall, we actually expanded it to 48 continental states. And so about 22 of those states who no longer need a physician order and that's what we've also done with the other 26 states. Order and that's what we've also done at the other 26 states is we lit up a telehealth network with PWN to provide an order for consumers if they need it. So we're deeply engaged in this. We've worked out some of the kinks operationally from years ago with all those experiences and we're up and running.
And as I said in my prepared remarks, we're very pleased with the sequential improvement and sequentially actually month upon month and we're seeing some nice volume growth. And there is a segment now, this is all private pay and we priced it accordingly for private pay. And there is a segment where people rather could get some of these tests done without engaging their health care insurance company. So, up and running and we're pleased with its initial results. The second part of the question had to do with back to your are Mark, can you remind me of the second question?
Mark, are you still there?
No. Operator, we'll end it
from there. We'll take it from there. Well, thanks, everyone, for joining us today. We appreciate your support, and have a great day. Thank you.
Thank you for participating in the Quest Diagnostics' Q2 2019 conference call. A transcript of prepared remarks on this call will be posted later today on Quest Diagnostics' website at www.questdiagnostics.com. A replay of the call may be accessed online at www.questdiagnostics.com/ investor or by phone at 800-871-1320 for domestic callers or 402 280-1688 for international callers. Telephone replays will be available for